---
document_datetime: 2025-12-02 06:34:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/heplisav-b.html
document_name: heplisav-b.html
version: success
processing_time: 0.2862329
conversion_datetime: 2025-12-27 14:45:08.142052
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Heplisav B

[RSS](/en/individual-human-medicine.xml/67400)

##### Authorised

This medicine is authorised for use in the European Union

hepatitis B surface antigen Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Heplisav B](#news-on)
- [More information on Heplisav B](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Heplisav B is a vaccine for preventing hepatitis B virus infection in adults. It is also likely to prevent infection with the hepatitis D virus as this virus is only present in people with hepatitis B infection.

Heplisav B is used in accordance with official recommendations. It contains a protein from the hepatitis B virus.

Expand section

Collapse section

## How is Heplisav B used?

Heplisav B is given as two injections into the muscle of the upper arm 1 month apart.

For more information about using Heplisav B, see the package leaflet or contact your doctor or pharmacist.

## How does Heplisav B work?

Heplisav B is a vaccine. Vaccines work by preparing the immune system (the body's natural defences) to defend the body against a specific disease.

Heplisav B contains a protein found on the hepatitis B virus. When a person is given the vaccine, the immune system recognises the protein in the vaccine as foreign and makes antibodies against it. If the person then comes into contact with virus, these antibodies, together with other components of the immune system, will be able to fight off the virus more effectively and so help protect the person against the infection. The vaccine also contains an adjuvant to stimulate a better response.

## What benefits of Heplisav B have been shown in studies?

Results from three main studies involving over 13,000 participants showed that Heplisav B was more effective than Engerix B (another hepatitis B vaccine) at stimulating an immune response against the virus. Taken together the studies found that around 96% of people given Heplisav B developed enough antibodies to kill off the virus and protect against the disease compared with 80% of those given Engerix B.

People given Heplisav B also had higher levels of antibodies and sufficient levels developed earlier with Heplisav B than with Engerix B.

## What are the risks associated with Heplisav B?

The most common side effects with Heplisav B (which may affect more than 1 in 10 people) are pain at the injection site, headache, feeling generally unwell, tiredness, muscle pain and fever.

People who have a severe allergic reaction after the first dose should not have a second dose. The vaccine should also not be given to people allergic to yeast.

For the full list of restrictions and side effects, see the package leaflet.

## Why is Heplisav B authorised in the EU?

Studies have shown that Heplisav B provides protection against hepatis B infection in 96% of people given the vaccine. Side effects occurred slightly less frequently with this vaccine than with the comparator vaccine (Engerix B) and they are considered manageable.

The European Medicines Agency therefore concluded that Heplisav B's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Heplisav B?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Heplisav B have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Heplisav B are continuously monitored. Side effects reported with Heplisav B are carefully evaluated and any necessary action taken to protect patients.

## Other information about Heplisav B

Heplisav B received a marketing authorisation valid throughout the EU on 18 February 2021.

Heplisav B : EPAR - Medicine overview

Reference Number: EMA/27931/2021

English (EN) (110.26 KB - PDF)

**First published:** 01/03/2021

[View](/en/documents/overview/heplisav-b-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-405)

български (BG) (131.45 KB - PDF)

**First published:**

01/03/2021

[View](/bg/documents/overview/heplisav-b-epar-medicine-overview_bg.pdf)

español (ES) (124.74 KB - PDF)

**First published:**

01/03/2021

[View](/es/documents/overview/heplisav-b-epar-medicine-overview_es.pdf)

čeština (CS) (139.92 KB - PDF)

**First published:**

01/03/2021

[View](/cs/documents/overview/heplisav-b-epar-medicine-overview_cs.pdf)

dansk (DA) (110.18 KB - PDF)

**First published:**

01/03/2021

[View](/da/documents/overview/heplisav-b-epar-medicine-overview_da.pdf)

Deutsch (DE) (142.2 KB - PDF)

**First published:**

01/03/2021

[View](/de/documents/overview/heplisav-b-epar-medicine-overview_de.pdf)

eesti keel (ET) (97.45 KB - PDF)

**First published:**

01/03/2021

[View](/et/documents/overview/heplisav-b-epar-medicine-overview_et.pdf)

ελληνικά (EL) (131.97 KB - PDF)

**First published:**

01/03/2021

[View](/el/documents/overview/heplisav-b-epar-medicine-overview_el.pdf)

français (FR) (111.26 KB - PDF)

**First published:**

01/03/2021

[View](/fr/documents/overview/heplisav-b-epar-medicine-overview_fr.pdf)

hrvatski (HR) (131.03 KB - PDF)

**First published:**

01/03/2021

[View](/hr/documents/overview/heplisav-b-epar-medicine-overview_hr.pdf)

italiano (IT) (109.38 KB - PDF)

**First published:**

01/03/2021

[View](/it/documents/overview/heplisav-b-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (138.31 KB - PDF)

**First published:**

01/03/2021

[View](/lv/documents/overview/heplisav-b-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (139.11 KB - PDF)

**First published:**

01/03/2021

[View](/lt/documents/overview/heplisav-b-epar-medicine-overview_lt.pdf)

magyar (HU) (131.77 KB - PDF)

**First published:**

01/03/2021

[View](/hu/documents/overview/heplisav-b-epar-medicine-overview_hu.pdf)

Malti (MT) (138.54 KB - PDF)

**First published:**

01/03/2021

[View](/mt/documents/overview/heplisav-b-epar-medicine-overview_mt.pdf)

Nederlands (NL) (110.04 KB - PDF)

**First published:**

01/03/2021

[View](/nl/documents/overview/heplisav-b-epar-medicine-overview_nl.pdf)

polski (PL) (144.55 KB - PDF)

**First published:**

01/03/2021

[View](/pl/documents/overview/heplisav-b-epar-medicine-overview_pl.pdf)

português (PT) (110.49 KB - PDF)

**First published:**

01/03/2021

[View](/pt/documents/overview/heplisav-b-epar-medicine-overview_pt.pdf)

română (RO) (130.74 KB - PDF)

**First published:**

01/03/2021

[View](/ro/documents/overview/heplisav-b-epar-medicine-overview_ro.pdf)

slovenčina (SK) (130.38 KB - PDF)

**First published:**

01/03/2021

[View](/sk/documents/overview/heplisav-b-epar-medicine-overview_sk.pdf)

slovenščina (SL) (129.45 KB - PDF)

**First published:**

01/03/2021

[View](/sl/documents/overview/heplisav-b-epar-medicine-overview_sl.pdf)

Suomi (FI) (109.26 KB - PDF)

**First published:**

01/03/2021

[View](/fi/documents/overview/heplisav-b-epar-medicine-overview_fi.pdf)

svenska (SV) (109.7 KB - PDF)

**First published:**

01/03/2021

[View](/sv/documents/overview/heplisav-b-epar-medicine-overview_sv.pdf)

Heplisav B : EPAR - Risk management plan

English (EN) (612.58 KB - PDF)

**First published:** 01/03/2021

**Last updated:** 13/05/2024

[View](/en/documents/rmp/heplisav-b-epar-risk-management-plan_en.pdf)

## Product information

Heplisav B : EPAR - Product information

English (EN) (250.49 KB - PDF)

**First published:** 01/03/2021

**Last updated:** 31/03/2025

[View](/en/documents/product-information/heplisav-b-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-477)

български (BG) (336.42 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/bg/documents/product-information/heplisav-b-epar-product-information_bg.pdf)

español (ES) (260.37 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/es/documents/product-information/heplisav-b-epar-product-information_es.pdf)

čeština (CS) (288.04 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/cs/documents/product-information/heplisav-b-epar-product-information_cs.pdf)

dansk (DA) (216.51 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/da/documents/product-information/heplisav-b-epar-product-information_da.pdf)

Deutsch (DE) (235.17 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/de/documents/product-information/heplisav-b-epar-product-information_de.pdf)

eesti keel (ET) (239.9 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/et/documents/product-information/heplisav-b-epar-product-information_et.pdf)

ελληνικά (EL) (333.38 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/el/documents/product-information/heplisav-b-epar-product-information_el.pdf)

français (FR) (233.2 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/fr/documents/product-information/heplisav-b-epar-product-information_fr.pdf)

hrvatski (HR) (279.67 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/hr/documents/product-information/heplisav-b-epar-product-information_hr.pdf)

íslenska (IS) (225.49 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/is/documents/product-information/heplisav-b-epar-product-information_is.pdf)

italiano (IT) (233.35 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/it/documents/product-information/heplisav-b-epar-product-information_it.pdf)

latviešu valoda (LV) (310.64 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/lv/documents/product-information/heplisav-b-epar-product-information_lv.pdf)

lietuvių kalba (LT) (313.59 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/lt/documents/product-information/heplisav-b-epar-product-information_lt.pdf)

magyar (HU) (317.29 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/hu/documents/product-information/heplisav-b-epar-product-information_hu.pdf)

Malti (MT) (326.36 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/mt/documents/product-information/heplisav-b-epar-product-information_mt.pdf)

Nederlands (NL) (244.59 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/nl/documents/product-information/heplisav-b-epar-product-information_nl.pdf)

norsk (NO) (238.79 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/no/documents/product-information/heplisav-b-epar-product-information_no.pdf)

polski (PL) (320.44 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/pl/documents/product-information/heplisav-b-epar-product-information_pl.pdf)

português (PT) (229.63 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/pt/documents/product-information/heplisav-b-epar-product-information_pt.pdf)

română (RO) (341.92 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/ro/documents/product-information/heplisav-b-epar-product-information_ro.pdf)

slovenčina (SK) (287.5 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/sk/documents/product-information/heplisav-b-epar-product-information_sk.pdf)

slovenščina (SL) (282.34 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/sl/documents/product-information/heplisav-b-epar-product-information_sl.pdf)

Suomi (FI) (267.66 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/fi/documents/product-information/heplisav-b-epar-product-information_fi.pdf)

svenska (SV) (228.42 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

31/03/2025

[View](/sv/documents/product-information/heplisav-b-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0037 27/02/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Heplisav B : EPAR - All Authorised presentations

English (EN) (50.13 KB - PDF)

**First published:** 01/03/2021

**Last updated:** 27/07/2023

[View](/en/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-837)

български (BG) (106.55 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/bg/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_bg.pdf)

español (ES) (14.08 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/es/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_es.pdf)

čeština (CS) (106.11 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/cs/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (19.63 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/da/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (20.18 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/de/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (15.18 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/et/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (96.06 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/el/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_el.pdf)

français (FR) (47.67 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/fr/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (97.26 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/hr/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (14.14 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/is/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_is.pdf)

italiano (IT) (61.89 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/it/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (105.32 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/lv/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (100.75 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/lt/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (99.94 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/hu/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (110.87 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/mt/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (13.63 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/nl/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (14.5 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/no/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_no.pdf)

polski (PL) (103.83 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/pl/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_pl.pdf)

português (PT) (14.8 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/pt/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_pt.pdf)

română (RO) (96.35 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/ro/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (102.22 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/sk/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (101.77 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/sl/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (13.16 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/fi/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (19.71 KB - PDF)

**First published:**

01/03/2021

**Last updated:**

27/07/2023

[View](/sv/documents/all-authorised-presentations/heplisav-b-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Heplisav B Active substance hepatitis B surface antigen International non-proprietary name (INN) or common name hepatitis B surface antigen Therapeutic area (MeSH) Hepatitis B Anatomical therapeutic chemical (ATC) code J07BC01

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Heplisav B is indicated for the active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The use of Heplisav B should be in accordance with official recommendations.

It can be expected that hepatitis D will also be prevented by immunisation with Heplisav B as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.

## Authorisation details

EMA product number EMEA/H/C/005063

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Dynavax GmbH

Eichsfelder Strasse 11

Opinion adopted 10/12/2020 Marketing authorisation issued 18/02/2021 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Heplisav B : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (225.26 KB - PDF)

**First published:** 11/01/2022

**Last updated:** 31/03/2025

[View](/en/documents/procedural-steps-after/heplisav-b-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Heplisav B : EPAR - Public assessment report

Adopted

Reference Number: EMA/1767/2021

English (EN) (1.47 MB - PDF)

**First published:** 01/03/2021

[View](/en/documents/assessment-report/heplisav-b-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Heplisav B

Adopted

Reference Number: EMA/CHMP/601178/2020

English (EN) (121.53 KB - PDF)

**First published:** 11/12/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-heplisav-b_en.pdf)

#### News on Heplisav B

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020) 11/12/2020

#### More information on Heplisav B

- [EMEA-001127-PIP02-11-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001127-pip02-11-m02)
- [Post-marketing observational surveillance study to evaluate pregnancy outcomes among women who receive Heplisav-B or Engerix-B (DV2-HBV-28) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000304)
- [HEPLISAV-B® Pregnancy Registry: an observational study on the safety of HEPLISAV-B exposure in pregnant women and their offspring (DV2-HBV-27) - post-authorisation study](https://catalogues.ema.europa.eu/study/50523)
- [Post-Marketing Observational Surveillance Study to Evaluate the Occurrence of Acute Myocardial Infarction in Adults 18 Years of Age and Older Who Receive HEPLISAV-B® Compared with Another Hepatitis B Vaccine (DV2-HBV-25) - post-authorisation study](https://catalogues.ema.europa.eu/study/50453)
- [Post-Marketing Observational Surveillance Study to Evaluate the Incidence of New-Onset Immune-Mediated Diseases, Herpes Zoster, and Anaphylaxis in Adults 18 Years of Age and Older Who Receive HEPLISAV B® Compared with Another Hepatitis B Vaccine (DV2-HBV-26) - post-authorisation study](https://catalogues.ema.europa.eu/study/50456)

**This page was last updated on** 31/03/2025

## Share this page

[Back to top](#main-content)